Pantoprazole

also known as Pantoloc · PROTONIX · pantoprazole sodium · Antopral · Controloc · Magnesium Pantoprazole · Pantomed · pantoprazole sodium sesquihydrate · +2 more

Other / unclassified targets ATP4A via inhibition

Developed for: gastroesophageal reflux disease · peptic ulcer disease · Helicobacter pylori infectious disease · dyspepsia · active peptic ulcer disease · acute kidney injury · hemorrhagic disease · chemotherapy-induced toxicity
+27 more
· cirrhosis of liver · coronary artery disorder · esophageal varices · esophagitis · atrial fibrillation · autoimmune thrombocytopenic purpura · Barrett esophagus · cancer · congestive heart failure · diabetes mellitus · duodenal ulcer · end stage renal failure · esophageal varices with bleeding · gastrocutaneous syndrome · hereditary hemochromatosis · lung disorder · obstructive sleep apnea syndrome · platinum-induced ototoxicity · prostate cancer · stomach disorder · type 1 diabetes mellitus · type 2 diabetes mellitus · Zollinger-Ellison syndrome · gastric ulcer · osteoarthritis, knee · peptic esophagitis · ulcer disease
Investigated by: Boehringer Ingelheim · Wyeth is now a wholly owned subsidiary of Pfizer · Takeda · AstraZeneca · Kaohsiung Veterans General Hospital. · Assiut University
+108 more
· Bristol-Myers Squibb · Children's Mercy Hospital Kansas City · Eisai Inc. · GlaxoSmithKline · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · National Taiwan University Hospital · Piramal Clinical Research (Hyderabad, India) · PriCara, Unit of Ortho-McNeil, Inc. · Rigshospitalet, Denmark · Ruijin Hospital · Seoul National University Hospital · Teva Pharmaceuticals USA · The University of Texas Health Science Center, Houston · Universitaire Ziekenhuizen KU Leuven · University Health Network, Toronto · University of British Columbia · Abbott · Akdeniz University · Annadal stichting · Asofarma de México S.A de C.V. · Assistance Publique - Hôpitaux de Paris · Astellas Pharma Europe B.V. · Autonomous University of Nuevo León · Bayer · Bio-Kinetic Europe, Ltd. · Canadian Institutes of Health Research (CIHR) · Casa Sollievo della Sofferenza IRCCS · Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec · Centro InmunoQ, Mexico City · Centro Médico ABC Observatorio, Mexico City · Chiesi Farmaceutici S.p.A. · Children's Hospital of Philadelphia · Chong Kun Dang Pharmaceutical · Chulalongkorn University · Coordinación de Investigación en Salud, Mexico · Copenhagen Trial Unit, Center for Clinical Intervention Research · Dr. Morten Hylander Møller · EMS · Emory University · Eurofarma Laboratorios S.A. · F2G Ltd · Gastroenterology and Endocrinology, University Medicine of Goettingen · Gateway for Cancer Research · General Hospital of Shenyang Military Region · Green Cross Corporation · HK inno.N Corporation · Haemonetics Corporation · Hallym University Medical Center · Helwan University · Herzzentrum Goettingen · Hospital Ángeles Metropolitano, Mexico City · Hospital Ángeles, Clínica Londres, Mexico City · Incheon St.Mary's Hospital · Insel Gruppe AG, University Hospital Bern · Janssen Research & Development, LLC · Johann Wolfgang Goethe University Hospital · Juvenile Diabetes Research Foundation · King Saud University · Klemens Budde · Kwong Wah Hospital · LCMC Health · Loma Linda University · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Maastricht University Medical Center · McGill University · McMaster University · Medical Statistics, University Medicine of Goettingen · Medical University of Vienna · Merck KGaA, Darmstadt, Germany · Merck Serono S.A., Geneva · Mirati Therapeutics Inc. · Montreal Children's Hospital of the MUHC · National Institutes of Health (NIH) · National Science and Technology Council, Taiwan · all 114 on the full record

Regulatory milestones approvals, filings & regulatory actions · 9 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Label expansions (3)	US (FDA)	PROTONIX IV	—	2001-10-19 – 2024-08-12	fda.gov ↗
Label expansions (3)	US (FDA)	PROTONIX	—	2001-06-12 – 2009-11-12	fda.gov ↗
Approved	EU (EMA)	Pantozol Control	—	2009-06-11	europa.eu ↗
Approved	US (FDA)	PROTONIX	—	2000-02-02	fda.gov ↗
Filed	US (FDA)	—	—	—	“Sun Pharma filed its abbreviated new drug application for pantoprazole.” sunpharma.com ↗

Trials 115 · started per year

today

US approved 2000

EU approved 2009

198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 01 trial · 1 met primary
Phase 0	NCT05005910	Sep 2021 → Dec 2022	peptic ulcer disease	Uayporn Kaosombatwattana	Completed	Met primary
Phase 129 trials · 1 met primary
Phase 1	NCT07683793	Oct → Dec 2026 expected	—	Chiesi Farmaceutici S.p.A.	Not yet recruiting	No outcome recorded
Phase 1	NCT07800897	Aug 2026 → Mar 2027 expected	—	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 1	NCT04935112	Jul → Aug 2021	—	Mirati Therapeutics Inc.	Completed	No outcome recorded
Phase 1	NCT03095547	May → Jul 2017	invasive aspergillosis	F2G Ltd	Withdrawn	No outcome recorded
Phase 1	NCT02186652	Jun 2014 → Sep 2015	gastroesophageal reflux disease	Phillip Brian Smith	Completed	No outcome recorded
Phase 1	NCT01887743	Jun 2013 → Oct 2015	gastroesophageal reflux disease, obesity disorder	Children's Mercy Hospital Kansas City	Completed	No outcome recorded
Phase 1	NCT01847417	May → Jul 2013	peptic ulcer disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01847404	May → Jun 2013	peptic ulcer disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01703858	Sep 2012 → Jan 2013	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT01857609	Aug → Dec 2012	—	Seoul National University Hospital	Completed	No outcome recorded
Phase 1	NCT01163903	Jul 2010 → Mar 2014	cancer	University Health Network, Toronto	Completed	No outcome recorded
Phase 1	NCT01129427	Aug → Nov 2009	—	Sanofi	Completed	No outcome recorded
Phase 1	NCT00744419	May 2009 → Apr 2012	gastroesophageal reflux disease	University of Louisville	Completed	No outcome recorded
Phase 1	NCT00938366	Jan 2008 → Jan 2009	multiple sclerosis	Merck KGaA, Darmstadt, Germany	Completed	No outcome recorded
Phase 1	NCT00383916	Oct 2006	—	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 1	NCT00600041	May 2005 → Jan 2006	—	Herzzentrum Goettingen	Completed	No outcome recorded
Phase 1	NCT00835393	Dec 2003	—	Teva Pharmaceuticals USA	Completed	No outcome recorded
Phase 1	NCT00835588	Dec 2003	—	Teva Pharmaceuticals USA	Completed	Met primary
Phase 1	NCT02173730	Nov 2002 → Feb 2003	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02170610	Mar → May 2002	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02170623	Feb → Apr 2002	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02170636	Jan → Mar 2002	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02209831	Nov 2001 → Jan 2002	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02170896	Oct → Dec 2001	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02170805	Apr → Jun 2001	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02170766	Oct → Dec 2000	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02170740	Nov 1999 → Jan 2000	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02264106	Apr → Jun 1998	—	Boehringer Ingelheim	Completed	No outcome recorded
Phase 1	NCT02264119	Apr → Jul 1998	—	Boehringer Ingelheim	Completed	No outcome recorded

Phase 212 trials · 1 met primary
Phase 2	NCT07076914	Oct 2025 → Jan 2028 expected	non-small cell lung carcinoma, small cell lung carcinoma	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Not yet recruiting	No outcome recorded
Phase 2	NCT06706258	Jan 2025 → Dec 2026 expected	acute kidney injury	The University of Texas Health Science Center, Houston	Recruiting	No outcome recorded
Phase 2	NCT06861478	Oct 2024 → Aug 2026 overdue	—	Autonomous University of Nuevo León	Recruiting	No outcome recorded
Phase 2	NCT06154226	Jan → Sep 2024	acute kidney injury	The University of Texas Health Science Center, Houston	Completed	No outcome recorded
Phase 2	NCT03910647	Dec 2019 → Dec 2020	drug pseudoallergy	Assiut University	Unknown	No outcome recorded
Phase 2	NCT04022837	Nov 2019 → Nov 2020	drug pseudoallergy	Assiut University	Unknown	No outcome recorded
Phase 2	NCT03948477	Jun 2019 → Oct 2021	breast cancer, chemotherapy-induced toxicity	University of Auckland, New Zealand	Completed	Met primary
Phase 2	NCT01848457	Apr 2013 → Jan 2016	chemotherapy-induced toxicity, osteosarcoma, platinum-induced ototoxicity	Children's Hospital of Philadelphia	Completed	No outcome recorded
Phase 2	NCT01748500	Jan 2013 → Mar 2021	prostate cancer	University Health Network, Toronto	Completed	No outcome recorded
Phase 2	NCT00768651	Oct 2008 → Jul 2011	type 1 diabetes mellitus	University of Alberta	Completed	No outcome recorded
Phase 2	NCT00037570	Nov 2000 → Feb 2002	peptic ulcer disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 2	NCT00001191	Feb 1983 → Dec 2007	Zollinger-Ellison syndrome, gastrin-producing neuroendocrine tumor	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	No outcome recorded

Phase 2/31 trial
Phase 2/3	NCT01541735	Jan 2012 → Mar 2013	type 2 diabetes mellitus	Coordinación de Investigación en Salud, Mexico	Completed	No outcome recorded
Phase 319 trials · 3 met primary
Phase 3	NCT03177629	May 2017 → Jun 2020	Helicobacter pylori infectious disease, autoimmune thrombocytopenic purpura	Seoul National University Hospital	Unknown	Met primary
Phase 3	NCT02929563	Jan 2017 → Jan 2020	—	McMaster University	Completed	No outcome recorded
Phase 3	NCT01670552	Feb → Oct 2016	dyspepsia	EMS	Completed	Met primary
Phase 3	NCT02345239	Feb → Jun 2015	diabetes mellitus	McGill University	Unknown	No outcome recorded
Phase 3	NCT01710462	Aug 2013 → ?	gastroesophageal reflux disease	Eurofarma Laboratorios S.A.	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT01776424	Feb 2013 → Jul 2017	—	Bayer	Completed	No outcome recorded
Phase 3	NCT02726269	Jun 2012 → Mar 2014	Helicobacter pylori infectious disease	Asofarma de México S.A de C.V.	Completed	Met primary
Phase 3	NCT00699361	Aug → Dec 2008	congestive heart failure	Johann Wolfgang Goethe University Hospital	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT00367614	Jan → Aug 2007	gastroesophageal reflux disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00312806	May 2006 → Mar 2007	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 3	NCT00141817	Aug 2005 → Nov 2007	gastroesophageal reflux disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00195208	Jun → Nov 2005	esophagitis, gastroesophageal reflux disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00163306	May 2005 → ?	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 3	NCT00374101	Jan 2005 → Mar 2007	active peptic ulcer disease	Casa Sollievo della Sofferenza IRCCS	Completed	No outcome recorded
Phase 3	NCT00161096	Mar 2004 → Sep 2005	gastroesophageal reflux disease, peptic ulcer disease	UMC Utrecht	Unknown	No outcome recorded
Phase 3	NCT00161200	Dec 2002 → Oct 2006	Barrett esophagus	University of Medicine and Dentistry of New Jersey	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT00040495	Apr 2001 → Jan 2003	peptic ulcer disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00261300	Oct 2000 → Sep 2007	gastroesophageal reflux disease, peptic ulcer disease	Takeda	Completed	No outcome recorded
Phase 3	NCT01499693	—	—	Takeda	Withdrawn	No outcome recorded

Phase 441 trials · 2 met primary · 2 missed
Phase 4	NCT07611162	May 2026 → May 2030 expected	gastroesophageal reflux disease	University of Mons	Not yet recruiting	No outcome recorded
Phase 4	NCT05624229	Oct 2023 → Dec 2025 overdue	esophageal varices with bleeding	West China Hospital	Not yet recruiting	No outcome recorded
Phase 4	NCT06050824	Jul 2022 → Jul 2023	Helicobacter pylori infectious disease	Helwan University	Completed	No outcome recorded
Phase 4	NCT07354230	Jan 2022 → Sep 2024	atrial fibrillation	Pirogov Russian National Research Medical University	Completed	No outcome recorded
Phase 4	NCT04713969	Mar 2021 → Jan 2024	dyspepsia	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 4	NCT03908593	Oct 2019 → Dec 2023	peptic ulcer disease	Ruijin Hospital	Unknown	No outcome recorded
Phase 4	NCT03920306	Apr 2019 → Sep 2024	gastrocutaneous syndrome	University of British Columbia	Completed	No outcome recorded
Phase 4	NCT03038009	Oct 2018 → Sep 2020	active peptic ulcer disease	Ruijin Hospital	Withdrawn	No outcome recorded
Phase 4	NCT04248335	Jul 2018 → Dec 2024	gastroesophageal reflux disease, metabolic dysfunction-associated steatotic liver disease	Children's Mercy Hospital Kansas City	Completed	No outcome recorded
Phase 4	NCT03545243	Apr 2018 → Mar 2020	immune dysregulation, neurodevelopmental defects, and colitis	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 4	NCT02401035	May 2017 → Jun 2021	gastroesophageal reflux disease	Pfizer	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT03175731	May 2017 → Aug 2019	cirrhosis of liver, portal hypertension	Yanjing Gao	Completed	No outcome recorded
Phase 4	NCT02788123	Mar → May 2017	stomach disorder	Astellas Pharma Europe B.V.	Terminated	No outcome recorded Stop: Business
Phase 4	NCT02718261	Feb 2016 → Sep 2018	acute kidney injury, end stage renal failure	Insel Gruppe AG, University Hospital Bern	Completed	No outcome recorded
Phase 4	NCT02467621	Jan 2016 → Oct 2017	duodenal ulcer	Dr. Morten Hylander Møller	Completed	Missed primary
Phase 4	NCT02213887	Sep 2014 → Nov 2020	gastroesophageal reflux disease, psychotic disorder	University of British Columbia	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT02108184	Feb 2014 → Aug 2016	Helicobacter pylori infectious disease	Incheon St.Mary's Hospital	Unknown	No outcome recorded
Phase 4	NCT01735227	Nov 2012 → Oct 2013	acute coronary syndrome	Yaling Han	Unknown	No outcome recorded
Phase 4	NCT01737840	Oct 2012 → Jan 2013	dyspepsia	Akdeniz University	Completed	No outcome recorded
Phase 4	NCT01801280	Jan 2012 → Mar 2013	disease related to solid organ transplantation	Klemens Budde	Completed	No outcome recorded
Phase 4	NCT02703896	Jan 2012	lung disorder	King Saud University	Completed	No outcome recorded
Phase 4	NCT01214408	Mar → Jul 2011	peptic ulcer disease	Abbott	Completed	No outcome recorded
Phase 4	NCT01281501	Jan → Oct 2011	dyspepsia	Chulalongkorn University	Completed	Missed primary
Phase 4	NCT01769365	Jul 2010 → Oct 2013	Helicobacter pylori infectious disease	Kaohsiung Veterans General Hospital.	Completed	Met primary
Phase 4	NCT00950339	Aug 2009 → Jun 2011	coronary artery disorder	Tel-Aviv Sourasky Medical Center	Completed	No outcome recorded
Phase 4	NCT00930670	Jun 2009 → Dec 2011	coronary artery disorder	Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec	Completed	No outcome recorded
Phase 4	NCT01023360	May 2008 → Oct 2010	—	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT00713947	Apr 2008 → Mar 2009	coronary thrombosis	Assistance Publique - Hôpitaux de Paris	Withdrawn	No outcome recorded
Phase 4	NCT01112852	Dec 2006 → Apr 2010	esophageal varices, hemorrhagic disease	National Science and Technology Council, Taiwan	Completed	No outcome recorded
Phase 4	NCT00410592	Oct 2006 → May 2007	gastroesophageal reflux disease	AstraZeneca	Completed	Met primary
Phase 4	NCT00325676	Jun 2006 → ?	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 4	NCT00246909	Nov 2005 → Nov 2006	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 4	NCT00261339	Aug 2005 → ?	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 4	NCT00206050	Sep → Dec 2004	—	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00307944	Aug 2004 → Aug 2006	gastroesophageal reflux disease, obstructive sleep apnea syndrome	University of Cincinnati	Completed	No outcome recorded
Phase 4	NCT00133770	Jul 2004 → Jul 2006	esophagitis	Emory University	Completed	No outcome recorded
Phase 4	NCT00625274	Jun → Nov 2004	dyspepsia, gastroesophageal reflux disease	AstraZeneca	Completed	No outcome recorded
Phase 4	NCT00304421	Jan 2004 → Sep 2007	gastroesophageal reflux disease	VA Greater Los Angeles Healthcare System	Completed	No outcome recorded
Phase 4	NCT00279123	Jan 2002 → ?	peptic ulcer disease	Kwong Wah Hospital	Completed	No outcome recorded
Phase 4	NCT00237367	? → Apr 2005	gastroesophageal reflux disease	PriCara, Unit of Ortho-McNeil, Inc.	Completed	No outcome recorded
Phase 4	NCT02123498	? → May 2015	eustachian tube disorder, gastroesophageal reflux disease	Loma Linda University	Withdrawn	No outcome recorded

Phase not applicable12 trials · 2 met primary · 2 missed
—	NCT07248722	Mar 2026 → Dec 2027 expected	cirrhosis of liver, esophageal varices	General Hospital of Shenyang Military Region	Enrolling by invitation	No outcome recorded
—	NCT06710600	Sep 2022 → Apr 2024	photosensitivity disease	Medical University of Vienna	Completed	No outcome recorded
—	NCT05353933	May → Jul 2022	gastroesophageal reflux disease	University of Medicine and Pharmacy at Ho Chi Minh City	Completed	Met primary
—	NCT03321773	Jan 2017 → Dec 2020	Helicobacter pylori infectious disease	Kaohsiung Veterans General Hospital.	Unknown	No outcome recorded
—	NCT03814421	Apr 2016 → Dec 2018	active peptic ulcer disease	Samsung Changwon Hospital	Unknown	No outcome recorded
—	NCT02788591	Aug 2015 → Jun 2021	gastroesophageal reflux disease	LCMC Health	Terminated	No outcome recorded Stop: Enrollment
—	NCT02159976	Jul 2014 → May 2015	Helicobacter pylori infectious disease	Seoul National University Bundang Hospital	Completed	Missed primary
—	NCT02541864	Jul 2013 → Aug 2015	Helicobacter pylori infectious disease	Kaohsiung Veterans General Hospital.	Completed	No outcome recorded
—	NCT01524757	Mar 2012 → Aug 2013	hereditary hemochromatosis	Maastricht University Medical Center	Unknown	Met primary
—	NCT01179724	Jul 2009 → Sep 2010	hemorrhagic disease	Samsung Medical Center	Unknown	No outcome recorded
—	NCT00709046	Jan 2008 → Jan 2010	hemorrhagic disease, peptic ulcer disease	National Taiwan University Hospital	Unknown	Missed primary
—	NCT00247715	Oct 2003 → Jan 2007	dyspepsia	Radboud University Medical Center	Completed	No outcome recorded

Comparator or background therapy91 trials
Phase 1	NCT06856447 Background	Jun 2024 → May 2025 overdue	colorectal cancer	toqa saad mohammed mohammed	Recruiting	No outcome recorded
Phase 1	NCT07262736 Comparator	Feb 2021 → Feb 2022	—	Universiti Sains Malaysia	Completed	No outcome recorded
Phase 1	NCT03011996 Comparator	May 2016 → Feb 2017	—	HK inno.N Corporation	Completed	No outcome recorded
Phase 1	NCT02214433 Background	Aug 2014 → Feb 2015	bacterial infectious disease	Debiopharm International SA	Completed	No outcome recorded
Phase 1	NCT01821521 Comparator	Jun → Aug 2013	—	Ahn-Gook Pharmaceuticals Co.,Ltd	Unknown	No outcome recorded
Phase 1	NCT01146483 Comparator	Apr 2010 → Dec 2011	—	University of Montreal Hospital Centre (CHUM)	Completed	No outcome recorded
Phase 1	NCT01170533 Comparator	Mar 2009 → Aug 2010	—	University of Florida	Completed	No outcome recorded
Phase 1	NCT01882296 Comparator	? → Sep 2013	—	Ahn-Gook Pharmaceuticals Co.,Ltd	Unknown	No outcome recorded
Phase 1/2	NCT06481306 Background	Jul 2024 → Apr 2028 expected	sickle cell disease	Bristol-Myers Squibb	Recruiting	No outcome recorded
Phase 2	NCT07293910 Comparator	Feb → Dec 2026 expected	Helicobacter pylori infectious disease	Tanta University	Recruiting	No outcome recorded
Phase 2	NCT06488001 Comparator	Aug 2022 → Dec 2026 expected	—	United States Naval Medical Center, Portsmouth	Recruiting	No outcome recorded
Phase 2	NCT05251233 Comparator	Apr 2022 → Jun 2024	ampulla of vater cancer, distal biliary tract carcinoma, malignant pancreatic neoplasm, pancreatic neuroendocrine tumor +1	Washington University School of Medicine	Terminated	No outcome recorded
Phase 2	NCT04821310 Comparator	Jan 2022 → Dec 2025	esophagitis	Pfizer	Terminated	No outcome recorded Stop: Business
Phase 2	NCT04221165 Background	Aug 2020 → Sep 2023	head and neck cancer, mucositis	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	Met primary
Phase 2	NCT02637557 Background	Mar 2016 → Apr 2017	gastroesophageal reflux disease	Ironwood Pharmaceuticals, Inc.	Completed	Met primary
Phase 2	NCT02142712 Comparator	Dec 2014	brain edema, stroke disorder	University of Florida	Completed	No outcome recorded
Phase 2	NCT00978016 Background	Sep 2009 → Dec 2010	gastroesophageal reflux disease	XenoPort, Inc.	Completed	Missed primary
Phase 2/3	NCT06531642 Comparator	Sep 2024 → Jul 2026 overdue	acute kidney injury	The University of Texas Health Science Center, Houston	Recruiting	No outcome recorded
Phase 2/3	NCT06062719 Background	Aug 2023 → Sep 2024	—	National Hepatology & Tropical Medicine Research Institute	Unknown	No outcome recorded
Phase 2/3	NCT05293132 Background	Feb 2022 → Jun 2023	infectious disease with sepsis	Ain Shams University	Completed	Met primary
Phase 2/3	NCT02685748 Background	Jul 2017 → Dec 2019	schizophrenia	Clinic for Psychiatric Disorders, Dr Laza Lazarevic	Completed	Missed primary
Phase 2/3	NCT00674245 Comparator	Apr 2008 → Jul 2010	gastroesophageal reflux disease	Southern Arizona VA Health Care System	Completed	No outcome recorded
Phase 2/3	NCT00403364 Background	Jul 2003 → Feb 2006	Helicobacter pylori infectious disease	IRCCS Azienda Ospedaliero-Universitaria di Bologna	Completed	Met primary
Phase 3	NCT07275827 Comparator	Feb → Dec 2026 expected	Helicobacter pylori infectious disease	Tanta University	Recruiting	No outcome recorded
Phase 3	NCT06414707 Comparator	Oct 2023 → Apr 2024	Helicobacter pylori infectious disease	Ain Shams University	Completed	No outcome recorded
Phase 3	NCT05227833 Comparator	Feb → Nov 2022	esophageal varices with bleeding, portal hypertension, ulcer disease	Alexandria University	Completed	No outcome recorded
Phase 3	NCT04107194 Background	Jan 2020 → Feb 2021	Helicobacter pylori infectious disease	University of Bari	Unknown	No outcome recorded
Phase 3	NCT04217512 Comparator	May 2019 → Dec 2030 expected	—	Tanta University	Recruiting	No outcome recorded
Phase 3	NCT03374800 Comparator	Jul 2018 → Oct 2023	peptic ulcer disease	McMaster University	Completed	No outcome recorded
Phase 3	NCT03998969 Background	Jun 2016 → Dec 2018	esophageal disorder	Seoul National University Hospital	Completed	No outcome recorded
Phase 3	NCT02533349 Comparator	May → Dec 2016	gastroesophageal reflux disease	Samsung Medical Center	Unknown	No outcome recorded
Phase 3	NCT02290327 Comparator	May 2015 → Jan 2016	—	McMaster University	Completed	No outcome recorded
Phase 3	NCT02084420 Comparator	Dec 2012 → Jan 2014	peptic ulcer disease	Il-Yang Pharm. Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT01132638 Comparator	Aug 2011 → Jun 2012	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 3	NCT01182597 Comparator	Aug 2010 → Aug 2013	peptic ulcer disease	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 3	NCT00857597 Comparator	Mar 2009 → Dec 2011	gastroesophageal reflux disease	University of Pittsburgh	Terminated	No outcome recorded
Phase 3	NCT00326027 Comparator	Oct 2006 → Jul 2007	gastroesophageal reflux disease	Nycomed	Completed	No outcome recorded
Phase 3	NCT00365300 Comparator	Sep 2006 → Nov 2007	gastroesophageal reflux disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00336219 Comparator	Aug → Nov 2006	gastroesophageal reflux disease	Takeda	Completed	No outcome recorded
Phase 3	NCT00362609 Comparator	Jul 2006 → Dec 2007	gastroesophageal reflux disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00300755 Comparator	May 2006 → Apr 2008	gastroesophageal reflux disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00868296 Comparator	Mar 2006 → Mar 2008	gastroesophageal reflux disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 3	NCT00259012 Comparator	Nov 2005 → Mar 2008	gastroesophageal reflux disease	Wyeth is now a wholly owned subsidiary of Pfizer	Completed	No outcome recorded
Phase 4	NCT07843264 Comparator	Oct 2026 → Dec 2027 expected	peptic esophagitis	University of Florida	Not yet recruiting	No outcome recorded
Phase 4	NCT06564246 Comparator	Sep 2024 → Aug 2026 overdue	gastroesophageal reflux disease	Tanta University	Recruiting	No outcome recorded
Phase 4	NCT06991348 Comparator	Jul 2024 → Nov 2025 overdue	gastroesophageal reflux disease	Carnot Laboratories	Recruiting	No outcome recorded
Phase 4	NCT04728516 Comparator	Apr 2023 → Jun 2026 overdue	Helicobacter pylori infectious disease, acute coronary syndrome	Qilu Hospital of Shandong University	Recruiting	No outcome recorded
Phase 4	NCT04660123 Background	Dec 2020 → Dec 2021	Helicobacter pylori infectious disease, gastric cancer	Xijing Hospital of Digestive Diseases	Completed	No outcome recorded
Phase 4	NCT04410536 Background	Jun 2020 → Dec 2021	migraine disorder	Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta	Completed	No outcome recorded
Phase 4	NCT03094416 Background	Jul 2018 → Jun 2020	postsurgical hypothyroidism	IBSA Institut Biochimique SA	Completed	No outcome recorded
Phase 4	NCT02987920 Background	Jan 2017 → Jan 2018	—	University of Southern California	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT02432456 Background	Sep 2015 → Aug 2018	—	Medical College of Wisconsin	Completed	Missed primary
Phase 4	NCT02466919 Background	May 2014 → Sep 2016	Helicobacter pylori infectious disease	Chung-Tai Wu	Completed	No outcome recorded
Phase 4	NCT02028234 Comparator	Feb 2014 → Mar 2015	coronary artery disorder	University of Roma La Sapienza	Unknown	No outcome recorded
Phase 4	NCT01016717 Comparator	Dec 2012	coronary artery disorder	Sheba Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT01493557 Comparator	Dec 2011 → Jul 2014	atrial fibrillation	Boehringer Ingelheim	Completed	No outcome recorded
Phase 4	NCT01373970 Comparator	May 2011 → May 2013	dyspepsia	Zealand University Hospital	Terminated	No outcome recorded
Phase 4	NCT02757703 Comparator	May 2010 → Jan 2015	esophageal varices with bleeding	Kaohsiung Veterans General Hospital.	Completed	No outcome recorded
Phase 4	NCT00825630 Comparator	Nov 2008 → Nov 2009	Helicobacter pylori infectious disease	Meridian Bioscience, Inc.	Completed	No outcome recorded
Phase 4	NCT00841854 Comparator	Jun 2008 → May 2010	Helicobacter pylori infectious disease	Asan Medical Center	Completed	No outcome recorded
Phase 4	NCT00731601 Comparator	May 2008 → Mar 2009	peptic ulcer disease	Lotung Poh-Ai Hospital	Completed	No outcome recorded
Phase 4	NCT00839488 Comparator	Apr 2008 → Mar 2009	gastric ulcer	Far Eastern Memorial Hospital	Terminated	No outcome recorded
Phase 4	NCT00449813 Comparator	Mar → Oct 2007	gastroesophageal reflux disease	Takeda	Terminated	No outcome recorded
Phase 4	NCT00863837 Comparator	Dec 2006 → Nov 2009	esophageal varices with bleeding	National Science and Technology Council, Taiwan	Unknown	No outcome recorded
Phase 4	NCT00843063 Comparator	Aug 2004 → Dec 2008	peptic ulcer disease	Ruttonjee Hospital	Completed	No outcome recorded
Phase 4	NCT00881413 Comparator	—	peptic ulcer disease	Lotung Poh-Ai Hospital	Withdrawn	No outcome recorded Stop: Business
—	NCT04566250 Background	Feb 2021 → Apr 2022	—	McMaster University	Completed	Met primary
—	NCT04394663 Comparator	Oct 2020 → May 2025 overdue	—	King Chulalongkorn Memorial Hospital	Recruiting	No outcome recorded
—	NCT04566211 Comparator	Jan 2020 → Sep 2022	Helicobacter pylori infectious disease	Kaohsiung Veterans General Hospital.	Unknown	No outcome recorded
—	NCT04621487 Comparator	Jan 2019 → Jan 2020	Helicobacter pylori infectious disease	University of Split, School of Medicine	Completed	No outcome recorded
—	NCT04697641 Background	Sep 2017 → May 2019	Helicobacter pylori infectious disease, dyspepsia	Sir Ganga Ram Hospital	Completed	Missed primary
—	NCT03058471 Comparator	Dec 2016 → Oct 2017	chikungunya	Post Graduate Institute of Medical Education and Research, Chandigarh	Completed	No outcome recorded
—	NCT02759029 Comparator	Mar 2016 → Feb 2018	Helicobacter pylori infectious disease	Gangnam Severance Hospital	Unknown	No outcome recorded
—	NCT03812419 Comparator	Jan → Dec 2016	—	Future University in Egypt	Completed	No outcome recorded
—	NCT02502877 Background	Jul 2015 → Mar 2016	—	Hospital da Luz, Portugal	Completed	No outcome recorded
—	NCT02547038 Background	Feb 2015 → Oct 2018	Helicobacter pylori infectious disease	Kaohsiung Veterans General Hospital.	Completed	Met primary
—	NCT02243618 Comparator	Jan 2015 → Apr 2016	gastric adenoma, gastric carcinoma	Yonsei University	Completed	No outcome recorded
—	NCT02235311 Comparator	Oct 2014 → Aug 2015	—	University of Missouri-Columbia	Terminated	No outcome recorded Stop: Enrollment
—	NCT02167633 Background	Jul 2014 → Sep 2016	metastatic malignant neoplasm, spinal cord disorder	Rigshospitalet, Denmark	Terminated	No outcome recorded Stop: Enrollment
—	NCT01477320 Comparator	Sep 2013 → Jul 2016	Clostridium difficile colitis	Mohamed Saad	Completed	No outcome recorded
—	NCT01744314 Background	Nov 2012 → Nov 2019	—	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Unknown	No outcome recorded
—	NCT02359435 Background	Oct 2012 → Feb 2015	Helicobacter pylori infectious disease	Kaohsiung Veterans General Hospital.	Completed	No outcome recorded
—	NCT02733640 Comparator	Oct 2012 → May 2015	platelet aggregation, spontaneous	Seoul National University Bundang Hospital	Completed	No outcome recorded
—	NCT02551744 Comparator	Jul 2012 → Jul 2018	peptic ulcer disease	Kaohsiung Veterans General Hospital.	Completed	No outcome recorded
—	NCT01643785 Background	Jun 2012 → Jun 2013	Helicobacter pylori infectious disease	Chuncheon Sacred Heart Hospital	Terminated	No outcome recorded
—	NCT01535001 Comparator	Feb 2012 → Sep 2014	osteoarthritis, knee	Northern Orthopaedic Division, Denmark	Completed	No outcome recorded
—	NCT04352062 Background	Jan 2011 → Oct 2018	—	Medical University of Lodz	Completed	No outcome recorded
—	NCT01167101 Background	May 2009 → Dec 2010	gastric ulcer	Kangdong Sacred Heart Hospital	Completed	No outcome recorded
—	NCT00681005 Comparator	Apr 2006 → Jan 2008	gastroesophageal reflux disease	National Taiwan University Hospital	Completed	No outcome recorded
—	NCT00915239 Comparator	Jan → Oct 2006	—	Sahlgrenska University Hospital	Completed	No outcome recorded
—	NCT00153725 Background	Feb 2003 → Sep 2006	cerebrovascular disorder	Chinese University of Hong Kong	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 6

Date	Issuer	Release
2025-04-01	Alembic Pharmaceuticals Ltd.	Regulatory Press Release FA for Pantoprazole Sodium injection 40 mgvial (Single Dose Vial) alembicpharmaceuticals.com ↗ Alembic Pharmaceuticals Limited (Alembic) announced that it has received Final Approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDAPantoprazole Sodium for Injection, 40 mg/vial (Single-Dose Vial).
2022-11-28	HK inno.N Corporation	Results HK inno.N presents K-CAB big data hepatotoxicity inno-n.com ↗ The study showed that K-CAB had a 27% lower risk of hepatotoxicity compared to six competitor PPI drugs.
2011-01-21	Wockhardt	Regulatory Wockhardt launches generic version of Protonix tablets in the US wockhardt.com ↗ Pharmaceutical and biotechnology major Wockhardt has received final approval from the United States Food & Drug Administration (US FDA) for marketing 20mg and 40mg Pantoprazole Delayed Release tablets of Pantoprazole (Protonix) that is used for treatment of GI Ulcers and hyperacidity.
2007-09-11	Sun Pharmaceutical Industries, Inc.	Regulatory Sun Pharma announces USFDA approval to market generic Protonix Tablets - Company gets its first 180 day marketing exclusivity on a first-to-file ANDA with para IV certification sunpharma.com ↗ Sun Pharmaceutical Industries Ltd. announced that USFDA has granted final approval for the company’s Abbreviated New Drug Applicat ion (ANDA) to market its generic version of Wyeth’s Protonix ®, pantoprazole tablets.
2007-08-02	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Announces Approval Of Generic Protonix® Delayed Release Tablets, 20 Mg And 40 Mg tevapharm.com ↗ the U.S. Food and Drug Administration has granted final approval for the Company's Abbreviated New Drug Application (ANDA)
2006-04-23	Teva Branded Pharmaceutical Products R&D, Inc.	Regulatory Teva Receives Tentative Approval for Generic Protonix® Delayed Release Tablets, 20 Mg And 40 Mg tevapharm.com ↗ the U.S. Food and Drug Administration has granted tentative approval for the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Wyeth's Protonix® (Pantoprazole Sodium) Delayed Release (DR) Tablets, 20 mg and 40 mg.

All press releases naming this drug 21 releases

Date	Issuer	Release
2025-04-01	Alembic Pharmaceuticals Ltd.	Press Release FA for Pantoprazole Sodium injection 40 mgvial (Single Dose Vial) alembicpharmaceuticals.com ↗
2022-11-28	HK inno.N Corporation	HK inno.N presents K-CAB big data hepatotoxicity inno-n.com ↗
2013-06-12	Sun Pharmaceutical Industries, Inc.	Sun Pharma settles generic Protonix® litigation sunpharma.com ↗
2013-06-12	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Reaches Settlement Agreement with Pfizer and Nycomed Regarding Generic Protonix® (Pantoprazole) Tablets tevapharm.com ↗
2012-02-15	Sun Pharmaceutical Industries, Inc.	Sun Pharma: An update on generic Protonix® litigation sunpharma.com ↗
2011-01-21	Wockhardt	Wockhardt launches generic version of Protonix tablets in the US wockhardt.com ↗
2010-07-17	Sun Pharmaceutical Industries, Inc.	Sun Pharma: an update on generic Protonix litigation® sunpharma.com ↗
2010-07-16	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Provides Update on Generic Protonix® Litigation tevapharm.com ↗
2010-04-24	Sun Pharmaceutical Industries, Inc.	Sun Pharma: an update on generic Protonix® litigation sunpharma.com ↗
2010-04-23	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Provides Update on Generic Protonix® Litigation tevapharm.com ↗
2009-05-14	Teva Branded Pharmaceutical Products R&D, Inc.	Federal Circuit Affirms Denial of Preliminary Injunction Regarding Teva's Generic Protonix® Tablets tevapharm.com ↗
2008-02-01	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Provides Update On Generic Protonix® tevapharm.com ↗
2008-01-30	Sun Pharmaceutical Industries, Inc.	Sun Pharma launches generic Protonix ® Tablets sunpharma.com ↗
2008-01-30	Prasco LLC	Prasco to Distribute Wyeth’s Own Generic Versions of Protonix® Delayed-Release Tablets prasco.com ↗
2008-01-30	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Wyeth Voids Standstill Agreement On Generic Protonix® tevapharm.com ↗
2008-01-22	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Extension To Standstill Agreement On Generic Protonix® tevapharm.com ↗
2007-12-24	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Launch of Generic Protonix® Tablets, 20 Mg and 40 Mg Company Increases 2007 EPS Guidance to Between $2.34 and $2.36 Company to Hold Conference Call at 8:45 A.M. Eastern Time tevapharm.com ↗
2007-09-11	Sun Pharmaceutical Industries, Inc.	Sun Pharma announces USFDA approval to market generic Protonix Tablets - Company gets its first 180 day marketing exclusivity on a first-to-file ANDA with para IV certification sunpharma.com ↗
2007-09-06	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives Favorable Court Decision Regarding Generic Protonix® Tablets; Motion For Preliminary Injunction Denied tevapharm.com ↗
2007-08-02	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Announces Approval Of Generic Protonix® Delayed Release Tablets, 20 Mg And 40 Mg tevapharm.com ↗
2006-04-23	Teva Branded Pharmaceutical Products R&D, Inc.	Teva Receives Tentative Approval for Generic Protonix® Delayed Release Tablets, 20 Mg And 40 Mg tevapharm.com ↗

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 206 sources stand behind the page.

Field	Value	Cited text
Known as	Pantoprazole	“14-day bismuth quadruple therapy (pantoprazole, bismuth subcitrate, tetracycline, and metronidazole for 14 days) or 14-day hybrid therapy (a 7-day dual therapy with...” PMID 28807915 ↗ Oct 2017 201 “Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40...” NCT00978016 ↗ “Group 2 will receive azithromycin 500 mg once daily (od) (Truxa®, Laboratorios Monte Verde SA, Argentina), levofloxacin 500 mg od (Laboratorios Asofarma de México SA de CV,...” NCT02726269 ↗ “All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium...” NCT02637557 ↗ “Oral anti-reflux therapy of either Pantoprazole 20-40mg PO OD, or Ranitidine 5-10mg/kg/day PO divided twice daily or 150mg PO BID, for either 4 weeks or until gastrocutaneous...” NCT03920306 ↗ “The aim of the study is to investigate whether intravenous infusion of pantoprazole (Pantoloc) is effective in preventing recurrent bleeding in patients who present with acute...” NCT00153725 ↗ “patients will receive concomitant therapy comprising of pantoprazole (40 mg twice daily), amoxicillin (1 gm twice a day), clarithromycin (500 mg twice a day) and metronidazole...” NCT06050824 ↗ “The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30...” NCT02502877 ↗ “versus continuous (40mg as a bolus injection followed by continuous infusion at 8mg/hr for 72hours) intravenous pantoprazole for prevention of bleeding after endoscopic therapy...” NCT03814421 ↗ “(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days :...” NCT02108184 ↗ “pantoprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg for the first 7 days, followed by pantoprazole 40 mg, amoxicillin 1 g for another 5 days” NCT02359435 ↗ Show 191 more sources
Known as	Antopral	“Pantoprazole (Controloc 40 mg OR Antopral 40 mg OR Perloc 40 mg), tablets” NCT05227833 ↗
Known as	Controloc	“Pantoprazole (Controloc 40 mg OR Antopral 40 mg OR Perloc 40 mg), tablets” NCT05227833 ↗
Known as	Magnesium Pantoprazole	ClinicalTrials.gov intervention name — accepted as the source's own label NCT01499693 ↗
Known as	Pantoloc	“The aim of the study is to investigate whether intravenous infusion of pantoprazole (Pantoloc) is effective in preventing recurrent bleeding in patients who present with acute...” NCT00153725 ↗ 6 “Pantoprazole 40 mg (Pantoloc) and placebo of vonoprazan (vonseca) daily for 8 weeks” NCT06564246 ↗ “Pantoprazole (Pantoloc) 3.3mg/hr for 72hrs” NCT01182597 ↗ “Drugs - Pantoloc 40mg, PO, BID, 1wk” NCT02759029 ↗ “pantoprazole (Pantoloc) 40mg” NCT06710600 ↗ NCT01112852 ↗ NCT00863837 ↗
Known as	Pantomed	“Pantoprazole (Pantomed®) 40mg once daily during 4 weeks” NCT03545243 ↗
Known as	pantoprazole sodium	“pantoprazole sodium enteric-coated spheroid suspension” NCT00259012 ↗ 1 “pantoprazole sodium enteric-coated spheroid” NCT00300755 ↗
Known as	pantoprazole sodium sesquihydrate	“All participants were taking a standard dose QD PPI (dexlansoprazole, esomeprazole, esomeprazole magnesium, lansoprazole, omeprazole, pantoprazole, pantoprazole sodium...” NCT02637557 ↗
Known as	Pantostad 40 CAP	“Oral pantoprazole 40 mg capsules (Pantostad 40 CAP, Stellapharm J.V. Co., Ltd, Binh Duong, Vietnam)” NCT05353933 ↗
Known as	Perloc	“Pantoprazole (Controloc 40 mg OR Antopral 40 mg OR Perloc 40 mg), tablets” NCT05227833 ↗
Known as	PROTONIX	“This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ®...” NCT00206050 ↗ 3 “Pantoprazole (Protonix) will be given at 6 different timepoints:” NCT06706258 ↗ “Protonix (Pantoprazole) 40 mg q 12 hrs for 2 days” NCT06531642 ↗ “Protonix” NCT02432456 ↗
Action	Inhibit	“Also investigated is the ability of the parenteral H+-K+ ATPase inhibitor, pantoprazole to control acid secretion short-term, when oral Omeprazole cannot be used.” NCT00001191 ↗
Modality	Other / unclassified	“Proton pump inhibitor” NCT03948477 ↗
Route	Intravenous	“intravenous pantoprazole” NCT00001191 ↗
Target	ATP4A	“Proton pump inhibitors (PPIs) block the ATP hydrolysis of the H+/K+ ATPase via binding its active site of ATP4A” NCT06706258 ↗